Role of the tissue-type plasminogen activator -7351C &gt; T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy

Malle, Eva Maria; Posch-Pertl, Laura; Renner, Wilfried; Pinter-Hausberger, Silke; Singer, Christoph; Haas, Anton; Wedrich, Andreas; Weger, Martin

doi:10.1080/13816810.2018.1536219

Cited by 6 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After adjusting for age and gender, researchers found that homozygosity for both tested gene variants was not significantly associated with the development of CSCR (PAI-1 4G/4G: OR=1.21, CI: 0.77-1.92, P=0.41 and t-PA -7351CC: OR=0.91, CI: 0.62-1.33, P=0.62). This study confirmed the findings of the Sari et al that also investigated the role of the PAI-1 4G/5G polymorphisms [57].…”

Section: Other Genes Studiessupporting

confidence: 92%

See 1 more Smart Citation

The Genetic Background of Central Serous Chorioretinopathy: A Review on Central Serous Chorioretinopathy Genes

Giannopoulos¹,

Gazouli²,

Chatzistefanou³

et al. 2021

J. Genomics

View full text Add to dashboard Cite

Central serous chorioretinopathy is characterized by neurosensory detachment of the central retina secondary to fluid leakage through the retinal pigment epithelium. Though it has an incidence of 9,9 per 100.000 in men and 1,7 per 100.000 in women, it is the fourth most common retinal disorder. Central serous chorioretinopathy patients present with blurred vision, central scotoma, metamorphopsia, micropsia and mild color discrimination. It is usually a self-limited disorder with nearly none or minimal visual impairment but in some patients the disease persists and may cause severe visual impairment. Central serous chorioretinopathy pathophysiology is not well understood. Choroid, retinal pigment epithelium and hormonal pathways seem to play important roles in central serous chorioretinopathy pathophysiology. Also, familial cases of the disease indicate that there is a genetic background. The identification of certain disease genes could lead to the development of better diagnostic and therapeutic approaches for central serous chorioretinopathy patients.

show abstract

Section: Other Genes Studiessupporting

confidence: 92%

“…PAI-1 plasma concentrations are affected by the PAI-1 promoter insertion/deletion of guanosine (4G/5G) polymorphism [53,56]. Higher PAI-1 levels were found among homozygotes of the PAI-1 4G allele compared to heterozygotes and homozygotes of the PAI-1 5G allele [57].…”

Section: Other Genes Studiesmentioning

confidence: 99%

The Genetic Background of Central Serous Chorioretinopathy: A Review on Central Serous Chorioretinopathy Genes

Giannopoulos¹,

Gazouli²,

Chatzistefanou³

et al. 2021

J. Genomics

View full text Add to dashboard Cite

show abstract

“…They reported although patients with acute CSCR have higher serum PAI-1 concentrations than the controls, no significant difference was found in the genotype disturbances of the PAI-1 gene between the groups. In a similar study, Malle et al 33 investigated the role of the tissue-type plasminogen activator (tPA) and PAI-1 gene polymorphisms in CSCR. They reported tPA and PAI-1 gene variants are unlikely major risk factors for CSCR.…”

Section: Discussionmentioning

confidence: 99%

Elevated serum fibrinogen/albumin ratios in patients with acute central serous chorioretinopathy

Limon

Bozkurt

Bulut

et al. 2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To evaluate the serum fibrinogen/albumin ratios in patients with acute and chronic central serous chorioretinopathy, and healthy control samples. Methods Serum fibrinogen/albumin ratios were assessed in patients with acute (Group-1, 30 eyes) and chronic (Group-2, 30 eyes) central serous chorioretinopathy, and compared with healthy control (Group-3, 30 eyes) samples. Results Fibrinogen/albumin ratios were significantly higher in Group-1 (104.72 ± 12.34) than in Group-2 (75.83 ± 10.06) and in Group-3 (72 ± 9.54) ( p = 0.001). No significant correlation was found between age, CMT, and BCVA with fibrinogen/albumin ratios in the Pearson correlation analysis. In the ROC curve analysis, the most appropriate cut-off value of the fibrinogen/albumin ratio for acute CSCR was ≥87.8 and the optimal cut-off value for the fibrinogen/albumin ratio for chronic CSCR was ≥68.6. Conclusion The fibrinogen/albumin ratio may be useful as an inflammatory biomarker to monitor the systemic inflammatory state during the treatment and follow-up in patients with acute CSCR.

show abstract

“…In patients with CSC, higher levels of plasminogen activator inhibitor have been reported in comparison with healthy subjects, and thus, it has been thought that hypercoagulability may represent a possible pathogenic factor related to CSC onset [ 37 ].…”

Section: Other Oral Pharmacological Treatment Options For Treatingmentioning

confidence: 99%

Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review

et al. 2020

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSC) is a common cause of visual impairment in patients generally aged 20 to 60 and it is characterized by acute or chronic neurosensory detachments of the retina. Although CSC resolves spontaneously in most cases, in some patients it may cause permanent visual impairment in the working population; for this reason, several approaches, including photodynamic therapy (PDT), subthreshold micropulse laser treatment and oral mineralocorticoid receptor antagonists, have been studied as first-line treatment options for CSC. To date, half-dose PDT has provided the most encouraging results in this regard, supported by large, multicenter, randomized clinical trials such as the “Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy” (PLACE) trial; however, the role of novel possible non-invasive treatment options is attracting interest. This review article aims to discuss the current pharmacological treatment options investigated for the management of CSC, including aspirin, ketoconazole, beta blockers, rifampicin and many others. In particular, further evidence about oral mineralocorticoid receptor antagonists, firstly seen as promising non-invasive alternatives for treating CSC, will be provided and discussed in light of the recent “Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months” (VICI) trial results, which have largely resized their role as possible first-line oral treatment options for treating CSC.

show abstract

Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy

Cited by 6 publications

References 25 publications

The Genetic Background of Central Serous Chorioretinopathy: A Review on Central Serous Chorioretinopathy Genes

The Genetic Background of Central Serous Chorioretinopathy: A Review on Central Serous Chorioretinopathy Genes

Elevated serum fibrinogen/albumin ratios in patients with acute central serous chorioretinopathy

Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review

Contact Info

Product

Resources

About